|
Dr. Spector, with 20 years of oncology experience, recently joined Duke University Medical Center's cancer drug development team as the new Director of Translational Research in Oncology. He also serves as Co-Director of the Experimental Therapeutics Program in the cancer center. Prior to joining Duke, Dr. Spector served as Director of GlaxoSmithKline's Exploratory Medical Sciences in Oncology, where he successfully developed two important cancer drugs, Tykerb (lapatinib) and Nelarabine (ara-G analog), from the bench to the clinic and then guided them through Food and Drug Administration (FDA) approval.
Dr. Spector received his medical degree from New Jersey Medical School, UMDNJ. He completed his internship and residency at University of Texas - Southwestern Parkland Memorial Hospital. His teaching experience also includes seven years at the Dana-Farber Cancer Institute in Boston and five years as an Assistant Professor of Medicine at the University of Miami. | 